Innoviva (INVA) Cash from Operations Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.95% |
| Sep 30, 2025 | 13.82% |
| Jun 30, 2025 | -11.19% |
| Mar 31, 2025 | -7.93% |
| Sep 30, 2024 | 17.66% |
| Jun 30, 2024 | -5.00% |
| Mar 31, 2024 | -13.53% |
| Sep 30, 2023 | 12.39% |
| Jun 30, 2023 | -5.89% |
| Mar 31, 2023 | -12.44% |
| Sep 30, 2022 | 34.70% |
| Jun 30, 2022 | 28.41% |
| Mar 31, 2022 | 28.72% |
| Sep 30, 2021 | 67.41% |
| Jun 30, 2021 | 46.68% |
| Mar 31, 2021 | 63.27% |
| Dec 31, 2020 | 65.27% |
| Sep 30, 2020 | 94.83% |
| Jun 30, 2020 | 105.56% |
| Mar 31, 2020 | 116.41% |
| Dec 31, 2019 | 75.21% |
| Sep 30, 2019 | 36.42% |
| Jun 30, 2019 | 24.89% |
| Mar 31, 2019 | 28.57% |
| Dec 31, 2018 | 28.81% |
| Sep 30, 2018 | 28.14% |
| Jun 30, 2018 | 38.52% |
| Mar 31, 2018 | 29.04% |
| Dec 31, 2017 | 31.77% |
| Sep 30, 2017 | 29.04% |
| Jun 30, 2017 | 21.60% |
| Mar 31, 2017 | 21.72% |
| Dec 31, 2016 | 23.14% |
| Sep 30, 2016 | 24.94% |
| Jun 30, 2016 | 21.99% |
| Mar 31, 2016 | 17.92% |
| Dec 31, 2015 | 19.72% |
| Sep 30, 2015 | 16.42% |